Cargando…
Specific Treatment Exists for SARS-CoV-2 ARDS
The COVID-19 pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), seems to be difficult to overcome. A pandemic of such a scale has not been seen since the 1918 influenza pandemic. Although the predominant clinical presentation is respiratory disease, neurological manife...
Autores principales: | Kanwar, Badar, Lee, Chul Joong, Lee, Jong-Hoon |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8229893/ https://www.ncbi.nlm.nih.gov/pubmed/34200720 http://dx.doi.org/10.3390/vaccines9060635 |
Ejemplares similares
-
Altered pre-existing SARS-CoV-2-specific T cell responses in elderly individuals
por: Taira, Naoyuki, et al.
Publicado: (2022) -
Defibrotide Therapy for SARS-CoV-2 ARDS
por: Frame, David, et al.
Publicado: (2022) -
Use of Spironolactone in SARS-CoV-2 ARDS Patients
por: Dumanlı, Güleren Yartaş, et al.
Publicado: (2020) -
(193) Coping with SARS-CoV-2-induced ARDS
por: Pancharovski, Tawnya, et al.
Publicado: (2022) -
Pre-Existing Comorbidities Diminish the Likelihood of Seropositivity after SARS-CoV-2 Vaccination
por: Amraotkar, Alok R., et al.
Publicado: (2022)